A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
Launched by ABBVIE · Sep 4, 2018
Trial Information
Current as of June 05, 2025
Suspended
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
- • Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
- • Participants who have been informed verbally and in writing about this study, and who do not object to their data being processed or subjected to data quality control.
- Exclusion Criteria:
- • - Participants currently participating (or previously participated) in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Be'er Sheva, Hadarom, Israel
Ramat Gan, Tel Aviv, Israel
Afula, , Israel
Haifa, , Israel
Haifa, , Israel
Jerusalem, , Israel
Jerusalem, , Israel
Kfar Saba, , Israel
Nahariya, , Israel
Petakh Tikva, , Israel
Rehovot, , Israel
Safed, , Israel
Tel Aviv, , Israel
Tel Aviv Yafo, Tel Aviv, Israel
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials